Document is current
Any future updates will be listed below
-
Authors
Pascual-Pasto, Guillem https://orcid.org/0000-0001-8537-261X
McIntyre, Brendan https://orcid.org/0000-0002-6473-5140
Hines, Margaret G.
Giudice, Anna M. https://orcid.org/0000-0002-3296-175X
Garcia-Gerique, Laura
Hoffmann, Jennifer
Mishra, Pamela
Matlaga, Stephanie
Lombardi, Simona
Shraim, Rawan
Schürch, Patrick M.
Yarmarkovich, Mark
Hofmann, Ted J.
Alikarami, Fatemeh
Martinez, Daniel
Tsang, Matthew
Gil-de-Gómez, Luis
Spear, Timothy T.
Bernt, Kathrin M. https://orcid.org/0000-0002-0691-356X
Wolpaw, Adam J. https://orcid.org/0000-0002-1373-7648
Dimitrov, Dimiter S. https://orcid.org/0000-0002-2258-1024
Li, Wei
Bosse, Kristopher R. https://orcid.org/0000-0002-1424-2858
-
Funding
Funding for this research was provided by:
Damon Runyon Cancer Research Foundation (PST-07-16)
EIF | Stand Up To Cancer (SU2C-AACR-DT-27-17)
Alex's Lemonade Stand Foundation for Childhood Cancer
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08 CA230223)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37 CA282041)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54 CA232568)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA266914)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Solving Kids' Cancer
Alex's Lemonade Stand Foundation for Childhood Cancer
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 3 October 2023
Accepted: 6 August 2024
First Online: 21 August 2024
Competing interests
: G.P.-P. and K.R.B. report having a pending patent directly related to this work entitled <i>Dual targeting of pediatric malignancies through CAR T cells secreting Bispecific Innate Immune Cell Engagers (BICEs)</i> (International Patent Application No. PCT/US2022/080935). M.Y., D.S.D., W.L. and K.R.B. hold patents for the discovery and development of other immunotherapies for cancer, including patents related to GPC2 and CD16a-directed immunotherapies. M.Y. is a co-founder of Hula Therapeutics. K.R.B. receives royalties and research funding from Tmunity/Kite Pharma and ConjugateBio for research on GPC2-directed immunotherapies. K.R.B. is on the ConjugateBio Scientific Advisory Board. K.M.B. has received research funding from Syndax. The remaining authors declare no competing interests.
